News Daily News Non-HDL Cholesterol Strongly Tied to Lifetime CVD Risk Michael O'Riordan December 03, 2019
News Conference News AHA 2019 Sex Differences, EF Thresholds Probed for Sacubitril/Valsartan in Heart Failure Shelley Wood November 22, 2019
News Conference News AHA 2019 Early Data Favorable for New RNAi Therapies to Reduce Triglycerides Caitlin E. Cox November 19, 2019
News Daily News FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl Michael O'Riordan November 14, 2019
News Daily News Testosterone Therapy Ups VTE Risk, Even When Indicated Caitlin E. Cox November 12, 2019
News Conference News AHA 2019 AHA 2019: Beyond ISCHEMIA Are Plenty of Coronary, Structural, and HF Trials Shelley Wood November 11, 2019
News Daily News Nighttime Hypertension Drug Dosing May Reduce Risk of CVD L.A. McKeown October 23, 2019
News Daily News New Review Questions Statin Benefit in Lower-Risk Primary Prevention Patients Michael O'Riordan October 22, 2019
News Daily News Disparate US Trends in Early CVD Deaths Speak to Need for Targeted Prevention Caitlin E. Cox October 21, 2019
News Daily News Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes L.A. McKeown October 21, 2019
News Daily News Walk and Talk: Step-Counting Devices Work Best When Paired With Doctor Consults Yael L. Maxwell October 10, 2019
News Daily News Dramatic Swings in Household Income Linked to CVD Risk: ARIC Michael O'Riordan October 09, 2019
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for September 2019 Shelley Wood October 01, 2019
News Daily News Lifetime Risk of PAD Varies by Race, but All Are Vulnerable to Traditional Risk Factors L.A. McKeown September 16, 2019
News Daily News High-Sensitivity Troponin T May Offer Glimpse Into Future HF Risk: ARIC Analysis L.A. McKeown September 13, 2019
News Daily News Greater Exposure to Toxins on 9/11 Left Firefighters at Increased Long-term CVD Risk L.A. McKeown September 11, 2019
News Conference News ESC 2019 New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL Michael O'Riordan September 05, 2019